Clinical Trial Update: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of QL0911 in adults with chronic primary immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• QL0911

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: COMPLETED